News and Conferences

Page 3 of 16

  1. DIAH Discovery to Innovation in Animal Health Conference

    Joseph Araujo, Chief Corporate Development Officer and Co-Founder, will attend the Discovery to Innovation in Animal Health Conference between May 19-21 in Bruges, Belgium.

  2. Pain Mechanisms and Therapeutics Conference

    Yassine Darbaky, Pain Subject Matter Expert, Business Development, will attend the Pain Mechanisms and Therapeutics Conference in Verona, Italy between May 17-22, 2026.

  3. Pain Therapeutics Summit Europe

    Yassine Darbaky, Pain Subject Matter Expert, Business Development, and Kris Rutten, Director of Business Development, will attend the Pain Therapeutics Summit Europe in Amsterdam, Netherlands between May 7-8, 2026.

  4. Swiss Biotech Day

    Jolanta Golec, Business Development Manager at Transpharmation, will attend the Swiss Biotech Day in Basel, Switzerland on May 4, 2026.

  5. OARSI Osteoarthritis Research Society International

    Joseph Araujo, Chief Corporate Development Officer and Co-Founder, and Whitney Kosziwka, Senior Scientific Director of Companion Animals, will attend OARSI Osteoarthritis Research Society International in West Palm Beach, FL, USA between April 23-26, 2026.

  6. CE BioForum

    Ewa Sokolowska, PhD, Senior Director of Transpharmation Poland, and Jolanta Golec, Business Development Manager at Transpharmation, will attend the CE BioForum in Warsaw, Poland between April 22-23, 2026. Dr. Ewa will participate in a panel discussion titled Smarter Science: Quo Vadis Testing. The panel will focus on the future of testing, including alternative and innovative approaches in preclinical and biomedical research.

  7. Hanson and Wade GLP-1 Based Therapeutics Summit

    Daniel Hutcheson, PhD, Chief Scientific Officer, will attend the Hanson and Wade GLP-1 Based Therapeutics Summit in Boston, MA, USA between April 14-16, 2026.

  8. BIO Europe Spring

    Joseph Araujo, Chief Corporate Development Officer and Co-Founder, will attend BIO Europe Spring in Lisbon, Portugal between March 23-25, 2026.

  9. ADPD International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

    Kris Rutten, Director of Business Development, and Ashley Bernardo, Senior Scientific Director of Rodent, will attend the ADPD International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders in Copenhagen, Denmark between March 17-21, 2026.

  10. AHNTI Animal Health Nutrition & Tech Innovation – Europe

    Joseph Araujo, Chief Corporate Development Officer and Co-Founder, will attend the AHNTI Animal Health Nutrition & Tech Innovation in London, UK between March 2-4, 2026.

Page 3 of 16

Want to see our latest study results?

Sign up for our newsletter.

Emails with our latest study results and news, from time to time. Unsubscribe anytime. See our Privacy Policy.

Newsletters

  • What's Next in CNS Drug Discovery? Five Studies Worth Exploring
  • Advancing Science Through In Vivo Refinement and Innovation - Examples from Abuse Liability and Impulsivity Screening
  • Building Confidence in Decision Making
  • Welcome to Reading, UK
  • The Next Leap in Translational Neuroscience
  • Expanding Scientific Possibility
  • 2025 Was A Year of Momentum: Science, People and Partners
  • 2025 Was A Year of Momentum: Science, People and Partners
  • Seven Posters, One Goal: Driving Neuroscience Forward
  • Advancing Preclinical Science for Next-Gen Therapies
  • New Capabilities Coming Online
  • Discover What's New at Transpharmation
  • Unlock the Microbiome: Transform Health with Transpharmation's Advanced Studies
  • Experimental Autoimmune Encephalomyelitis (EAE): Maximising The Therapeutic Efficacy of Fingolimod
  • Cross-Species Epilepsy Research: Revealing the Potential of the Zebrafish Model
  • Monoamine depletion to induce chronic allodynia and behavioural changes: a model of fibromyalgia
  • Take your R&D pipeline into the AI era with Moseq (Motion Sequencing), our new behavioural machine-learning assay!
  • Canine Microbiome
  • Oral Health: Not just for Humans
  • Novel Object Recognition: A Reliable Assay for Addressing Cognitive Impairments in Schizophrenia
  • Pre-pulse Inhibition: A Promising Screening Tool for Novel Compounds
  • Natural and induced models of osteoarthritis in Beagle dogs
  • Utilizing Rapid Screening Tests to Assess the Antidepressant Potential of Psychedelic Analogues
  • Long-term antidepressant effect of ketamine and psilocybin in the Chronic Social Defeat stress model
  • Diabetes and Metabolic Syndrome
  • Transpharmation's Animal Health Services
  • Longevity Research Goes to the Dogs
  • Transpharmation's Cutting-Edge Antiepileptic Drug Screening: A Global Solution for Advancing Epilepsy Research
  • PTZ-treated Zebrafish provide a high throughput platform for screening novel anti-epileptic drugs
  • Beyond Seizures: Epilepsy Comorbidities Explored in Mouse Kindling Studies
  • Novelty-suppressed feeding and novelty-induced hypophagia: exploring sex differences and response to diazepam in C57BL/6J mice.
  • Development & validation of intrathecal dosing in rats and mice
  • Transpharmation's Mouse-EEG capability reveals cross-species effects of novel antidepressants ketamine and psilocybin
  • Oral Health: Not just for Humans...
  • Accelerate Your Diabetes Drug Development with Transpharmation's Dog Diabetes Models
  • Introducing our new data analysis service for tremor-plate signals!
  • Introducing the Scn1a mutant mouse model of Dravet Syndrome at Transpharmation
  • New validated pre-clinical model to assess treatments for post-surgical pain
  • Experimental Autoimmune Encephalomyelitis; Modelling Multiple Sclerosis and Beyond
  • New Preclinical Models of Migraine for Assessment of Rescue and Preventive Analgesic Treatments
  • Do Your Compounds Exhibit Anti-Inflammatory Compounds
  • Profile your anti-inflammatory compounds in primary human immune cells
  • New EEG services from Transpharmation. Read on for results...
  • Accelerate your Drug Discovery Research. Proven results, fast and cost effective
  • Urgent Treatments Needed for Parkinson's Disease
  • Poor bioavailability, is the liver or intestine to blame?
  • Laser Doppler; new validated protocols revealed.
  • Epilepsy models leading the way. Read on for results.
  • Profiling anti-inflammatory drugs; from rodent to human
  • The Mismatch Negativity Challenge
  • Accelerate your drug discovery research. Proven science based results cost-effectively.
  • Anxiety. Three preclinical tests; data revealed...
  • Seven new posters, presented at SfN, now available to view.
  • Name change announcement! News from the CEO.
  • Chronic fatigue: different etiologies influence translational models
  • Seven new translational studies to share with you at this year's SfN event. Read on for poster titles and contact details.
  • Translational value increased with non-evoked pain measures.
  • Rapid access to PK non-rodent studies. Leading expertise.
  • Essential tremor research
  • Can a psychedelic experience be modelled in rats?
  • Gender Differences in Pain. New research revealed!
  • New data on the effect of single dose psilocybin!
  • From ketamine to psychedelics, join our webinar starting tomorrow!
  • Long term delayed effects of psychedelics in preclinical models. Trailblazing results revealed!
  • Accreditation awarded with flying colours
  • Breaking news! Merger announcement between Transpharmation and InterVivo Solutions.
  • Take a look! New posters, nine therapeutic areas available to view now.
  • Nine new compelling studies to be revealed at SfN21!
  • Can changes in EEG improve neuropathic pain treatments?
  • 40Hz ASSR: sounds that change our thoughts about schizophrenia
  • Clerkenwell Health and Transpharmation combine lab and human trials for psilocybin
  • Translational endpoints for preclinical pain - improving your chances.
  • Transpharmation aims for global standard. Let's talk about lab sustainability.
  • Targeting the unmet medical need in Parkinson's Disease - the fastest growing neurological disorder.
  • Psilocybin: the power of mental reorganisation
  • Expansion to world class premises
  • Multiple therapeutic indications
  • Focus on pain
  • Gene therapies for body and brain in Duchenne Muscular Dystrophy, progress moves forward.
  • Announcing Transpharmation Poland!